Research programme: vasopermeation enhancement agents - Peregrine

Drug Profile

Research programme: vasopermeation enhancement agents - Peregrine

Alternative Names: D2OT; NHS-IL-2; NHS76/PEP2

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Peregrine Pharmaceuticals
  • Class Monoclonal antibodies; Peptide fragments
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 23 Apr 2007 Preclinical development is ongoing
  • 18 Jan 2007 Preclinical development is ongoing
  • 20 Apr 2005 NHS76/PEP2 has been selected as the lead compound from this research programme
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top